US7053070B2
(en)
*
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
DK1333833T3
(da)
|
2000-10-23 |
2011-12-12 |
Glaxosmithkline Llc |
Ny trisubstitueret 8H-pyridol[2,3-d]pyrimidin-7-on-forbindelse til behandling af CSBP/RK/p38-kinnasemedierede sygdomme
|
DK1361880T3
(da)
*
|
2001-02-12 |
2006-01-23 |
Hoffmann La Roche |
6-substituerede pyrido-pyrimidiner
|
JP4166991B2
(ja)
*
|
2001-02-26 |
2008-10-15 |
田辺三菱製薬株式会社 |
ピリドピリミジンまたはナフチリジン誘導体
|
AU2002324450A1
(en)
*
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel pyridopyrimidines and uses thereof
|
US20030100572A1
(en)
*
|
2001-06-21 |
2003-05-29 |
Ariad Pharmaceuticals,Inc. |
Novel pyridopyrimidones and uses thereof
|
CA2473026C
(en)
*
|
2002-01-22 |
2011-05-03 |
Warner-Lambert Company Llc |
2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
|
US7629350B2
(en)
|
2002-04-19 |
2009-12-08 |
Smithkline Beecham Corporation |
Compounds
|
CA2494061C
(en)
|
2002-07-31 |
2011-06-14 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
EP1551824B1
(en)
|
2002-10-09 |
2007-12-12 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
BRPI0406809A
(pt)
*
|
2003-01-17 |
2005-12-27 |
Warner Lambert Co |
Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
AU2004268621C1
(en)
|
2003-08-29 |
2011-08-18 |
Exelixis, Inc. |
c-Kit modulators and methods of use
|
AU2004289428B2
(en)
|
2003-11-13 |
2010-06-03 |
F. Hoffmann-La Roche Ag |
Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004033670A1
(de)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
FR2873118B1
(fr)
|
2004-07-15 |
2007-11-23 |
Sanofi Synthelabo |
Derives de pyrido-pyrimidine, leur application en therapeutique
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
EP1630163A1
(de)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
JP2008510770A
(ja)
*
|
2004-08-26 |
2008-04-10 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Plk阻害剤としての新規プテリジノン
|
DE102004058337A1
(de)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
EP1856053A1
(en)
|
2005-01-14 |
2007-11-21 |
Millennium Pharmaceuticals, Inc. |
Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
|
MY145343A
(en)
|
2005-03-25 |
2012-01-31 |
Glaxo Group Ltd |
Novel compounds
|
JP2008535822A
(ja)
|
2005-03-25 |
2008-09-04 |
グラクソ グループ リミテッド |
新規化合物
|
EA200702073A1
(ru)
|
2005-03-25 |
2008-12-30 |
Глэксо Груп Лимитед |
Способ получения пиридо[2,3-d]пиримидин-7-оновых и 3,4-дигидропиримидо[4,5-d]пиримидин-2(1н)-оновых производных
|
UY29439A1
(es)
|
2005-03-25 |
2006-10-02 |
Glaxo Group Ltd |
Nuevos compuestos
|
US7737155B2
(en)
*
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
FR2887882B1
(fr)
*
|
2005-07-01 |
2007-09-07 |
Sanofi Aventis Sa |
Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
|
US7642270B2
(en)
|
2005-09-14 |
2010-01-05 |
Janssen Pharmaceutica N.V. |
5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
|
TW200800983A
(en)
|
2005-09-14 |
2008-01-01 |
Janssen Pharmaceutica Nv |
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
|
NZ566903A
(en)
*
|
2005-10-07 |
2011-09-30 |
Exelixis Inc |
Pyrido (2,3-D) pyrimidinone compounds and their use as PI3 inhibitors
|
CA2624965A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of pi3k.alpha.
|
FR2896246B1
(fr)
|
2006-01-13 |
2008-08-15 |
Sanofi Aventis Sa |
Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
MY146420A
(en)
|
2006-09-15 |
2012-08-15 |
Pfizer Prod Inc |
Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
|
EP1914234A1
(en)
*
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
AU2007311480A1
(en)
*
|
2006-10-16 |
2008-04-24 |
Forma Therapeutics, Inc. |
Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
|
WO2008055013A2
(en)
*
|
2006-10-31 |
2008-05-08 |
Janssen Pharmaceutica N.V. |
5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
|
FR2910813B1
(fr)
|
2006-12-28 |
2009-02-06 |
Sanofi Aventis Sa |
Nouvelle utilisation therapeutique pour le traitement des leucemies
|
BRPI0809998B8
(pt)
*
|
2007-04-03 |
2021-05-25 |
Array Biopharma Inc |
composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
|
LT2168966T
(lt)
|
2007-06-15 |
2017-01-10 |
Msd K.K. |
Bicikloanilino darinys
|
CA2695406A1
(en)
|
2007-08-03 |
2009-02-12 |
Boehringer Ingelheim International Gmbh |
Crystalline form of a dihydropteridione derivative
|
NZ586069A
(en)
|
2007-12-19 |
2012-05-25 |
Amgen Inc |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
US8466151B2
(en)
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
EP2100894A1
(en)
*
|
2008-03-12 |
2009-09-16 |
4Sc Ag |
Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
|
CA2719538C
(en)
*
|
2008-04-07 |
2014-03-18 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
EP2318406B1
(en)
|
2008-07-17 |
2016-01-27 |
Critical Outcome Technologies, Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
EP2350070A1
(en)
|
2008-09-30 |
2011-08-03 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of pi3k and mtor
|
TW201100441A
(en)
|
2009-06-01 |
2011-01-01 |
Osi Pharm Inc |
Amino pyrimidine anticancer compounds
|
US8372970B2
(en)
*
|
2009-10-09 |
2013-02-12 |
Afraxis, Inc. |
8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders
|
WO2011075616A1
(en)
|
2009-12-18 |
2011-06-23 |
Temple University - Of The Commonwealth System Of Higher Education |
Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
|
UY33221A
(es)
|
2010-02-09 |
2011-09-30 |
Univ California |
MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
EA022527B1
(ru)
*
|
2010-08-05 |
2016-01-29 |
Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн |
2-ЗАМЕЩЕННЫЕ-8-АЛКИЛ-7-ОКСО-7,8-ДИГИДРОПИРИДО[2,3-d]ПИРИМИДИН-6-КАРБОНИТРИЛЫ И ИХ ПРИМЕНЕНИЕ
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
PL2646448T3
(pl)
|
2010-11-29 |
2017-12-29 |
OSI Pharmaceuticals, LLC |
Makrocykliczne inhibitory kinazy
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
SG193580A1
(en)
|
2011-03-23 |
2013-10-30 |
Amgen Inc |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
MX347040B
(es)
*
|
2011-05-17 |
2017-04-10 |
Principia Biopharma Inc |
Inhibidores de tirosina-cinasas.
|
US9718821B2
(en)
|
2012-02-23 |
2017-08-01 |
Abbvie Inc. |
Pyridopyrimidinone inhibitors of kinases
|
EP2958916B1
(en)
*
|
2013-02-21 |
2018-09-12 |
Pfizer Inc |
Solid forms of a selective cdk4/6 inhibitor
|
WO2015011236A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
WO2016015598A1
(en)
|
2014-07-26 |
2016-02-04 |
Sunshine Lake Pharma Co., Ltd. |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
US10449195B2
(en)
|
2016-03-29 |
2019-10-22 |
Shenzhen Pharmacin Co., Ltd. |
Pharmaceutical formulation of palbociclib and a preparation method thereof
|
TWI646094B
(zh)
*
|
2016-06-01 |
2019-01-01 |
大陸商貝達藥業股份有限公司 |
Crystal form of inhibitory protein kinase active compound and application thereof
|
RS61934B1
(sr)
|
2016-08-15 |
2021-07-30 |
Pfizer |
Inhibitori piridopirimdinona cdk2/ 4/6
|
WO2018160076A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Auckland Uniservices Limited |
Fgfr kinase inhibitors and pharmaceutical uses
|
MA51846A
(fr)
|
2018-02-15 |
2021-04-21 |
Nuvation Bio Inc |
Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
|
WO2020114519A1
(zh)
*
|
2018-12-07 |
2020-06-11 |
杭州英创医药科技有限公司 |
作为cdk-hdac双通路抑制剂的杂环化合物
|
CN112759589B
(zh)
*
|
2019-11-01 |
2022-04-08 |
暨南大学 |
嘧啶并吡啶酮类化合物及其应用
|
CN114901659A
(zh)
|
2019-11-26 |
2022-08-12 |
施万生物制药研发Ip有限责任公司 |
作为jak抑制剂的稠合嘧啶吡啶酮化合物
|
AU2022234998A1
(en)
*
|
2021-03-08 |
2023-10-12 |
Jinan University |
Pyridopyrimidine compounds and applications thereof
|
WO2024056091A1
(zh)
*
|
2022-09-16 |
2024-03-21 |
华东师范大学 |
作为rsk抑制剂的吡啶酮并嘧啶衍生物及其应用
|
WO2024099403A1
(zh)
*
|
2022-11-10 |
2024-05-16 |
北京普祺医药科技股份有限公司 |
一种具有软药性质的硫醚类化合物、药物组合物及其用途
|
WO2024107730A1
(en)
*
|
2022-11-14 |
2024-05-23 |
Onconova Therapeutics, Inc. |
Methods and compositions for treating cancer
|